Compare RNW & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RNW | NVAX |
|---|---|---|
| Founded | 2011 | 1987 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 1.3B |
| IPO Year | 2021 | 1996 |
| Metric | RNW | NVAX |
|---|---|---|
| Price | $6.85 | $10.91 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 1 | 9 |
| Target Price | $7.00 | ★ $11.33 |
| AVG Volume (30 Days) | 2.1M | ★ 5.0M |
| Earning Date | 06-15-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 309.76 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,123,479,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $11.50 | N/A |
| P/E Ratio | $14.63 | ★ N/A |
| Revenue Growth | N/A | ★ 64.69 |
| 52 Week Low | $4.39 | $6.20 |
| 52 Week High | $8.24 | $11.85 |
| Indicator | RNW | NVAX |
|---|---|---|
| Relative Strength Index (RSI) | 64.23 | 67.58 |
| Support Level | $6.78 | $8.42 |
| Resistance Level | N/A | $10.85 |
| Average True Range (ATR) | 0.02 | 0.53 |
| MACD | -0.02 | 0.07 |
| Stochastic Oscillator | 56.52 | 83.08 |
ReNew Energy Global PLC is a developer and operator of clean energy projects. Additionally, it provides clean energy solutions and value-added energy offerings through digitalization, storage, and carbon market services that are increasingly integral to addressing climate change. The company has two reportable segments: Generation and sale of renewable power and Manufacturing of power equipment. The majority of its revenue is generated from the Generation and sale of renewable power segment, which reflects the revenue earned from its utility-scale wind energy projects, solar energy projects, and hydro energy projects. The Manufacturing of power equipment segment relates to the manufacturing of solar panels and modules. Geographically, all of its material revenues are generated from India.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.